rxstat › Shortages › Hydrochlorothiazide Irbesartan

Hydrochlorothiazide Irbesartan shortage status

Partial shortage

Source: Health Canada shortage reports · Updated Jul 9, 2026

Some Hydrochlorothiazide Irbesartan products are in shortage in Canada (13 of 35 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Dec 4, 2026.
Products affected
13 / 35
In shortage since
Sep 17, 2018
Est. full return
Dec 4, 2026
Reports on file
145
Talk to your pharmacist. Pharmacists can often substitute another manufacturer's version, a different strength, or (in most provinces) adapt or renew a prescription on the spot. Your free provincial health line is 811.

Reports by product

Active shortage
SANDOZ IRBESARTAN HCT
12.5MG 150MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02337428 · since Jun 29, 2026, est. end Dec 4, 2026 · Demand increase for the drug.
Active shortage
SANDOZ IRBESARTAN HCT
25MG 300MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02337444 · since May 19, 2026, est. end Aug 14, 2026 · Shortage of an active ingredient.
Active shortage
SANDOZ IRBESARTAN HCT
12.5MG 150MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02337428 · since Apr 6, 2026, est. end Sep 18, 2026 · Disruption of the manufacture of the drug.
Active shortage
PMS-IRBESARTAN-HCTZ
12.5MG 300MG · TABLET · PHARMASCIENCE INC
DIN 02328526 · since Nov 14, 2022, est. end Dec 1, 2026 · Disruption of the manufacture of the drug.
Active shortage
IRBESARTAN/HCTZ
12.5MG 150MG · TABLET · SANIS HEALTH INC
DIN 02372886 · since Nov 18, 2024, no end estimate · Disruption of the manufacture of the drug.
Active shortage
IRBESARTAN/HCTZ
12.5MG 300MG · TABLET · SANIS HEALTH INC
DIN 02372894 · since Oct 7, 2024, no end estimate · Disruption of the manufacture of the drug.
Active shortage
IRBESARTAN/HCTZ
25MG 300MG · TABLET · SANIS HEALTH INC
DIN 02372908 · since Jun 1, 2024, no end estimate · Disruption of the manufacture of the drug.
Active shortage
TEVA-IRBESARTAN HCTZ
300MG 25MG · TABLET · TEVA CANADA LIMITED
DIN 02330539 · since Mar 10, 2024, no end estimate · Disruption of the manufacture of the drug.
Active shortage
JAMP-IRBESARTAN AND HYDROCHLOROTHIAZIDE
150MG 12.5MG · TABLET · JAMP PHARMA CORPORATION
DIN 02418223 · since Oct 7, 2019, est. end Dec 30, 2022 · Disruption of the manufacture of the drug.
Active shortage
JAMP-IRBESARTAN AND HYDROCHLOROTHIAZIDE
25MG 300MG · TABLET · JAMP PHARMA CORPORATION
DIN 02418258 · since Oct 7, 2019, est. end Dec 30, 2022 · Disruption of the manufacture of the drug.
Active shortage
JAMP-IRBESARTAN AND HYDROCHLOROTHIAZIDE
25MG 300MG · TABLET · JAMP PHARMA CORPORATION
DIN 02418258 · since Oct 7, 2019, est. end Dec 30, 2022 · Disruption of the manufacture of the drug.
Active shortage
JAMP-IRBESARTAN AND HYDROCHLOROTHIAZIDE
25MG 300MG · TABLET · JAMP PHARMA CORPORATION
DIN 02418258 · since Oct 7, 2019, est. end Dec 30, 2022 · Disruption of the manufacture of the drug.

Showing 12 of 60 reports. All reports are on file with Health Canada.

What's happening

Hydrochlorothiazide Irbesartan is currently affected by 13 active shortage reports filed with Health Canada by SANDOZ CANADA INCORPORATED, PHARMASCIENCE INC, SANIS HEALTH INC, TEVA CANADA LIMITED and 2 others.

The reported causes are: demand increase for the drug; shortage of an active ingredient; disruption of the manufacture of the drug; requirements related to complying with good manufacturing practices. Manufacturers must report shortages, but end-date estimates are their own projections and often move.

If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.

Hydrochlorothiazide Irbesartan is classified under “ANGIOTENSIN II ANTAGONISTS, COMBINATIONS” (ATC C09DA).

Recent changes

Common questions

When will Hydrochlorothiazide Irbesartan be back in stock in Canada?

The latest manufacturer estimate is Dec 4, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.

Why is Hydrochlorothiazide Irbesartan in shortage?

See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Related drugs (angiotensin ii antagonists, combinations)

Partial shortageAmlodipine Telmisartan2 of 6 reported products affectedPartial shortageHydrochlorothiazide Candesartan Cilexetil4 of 21 reported products affected · est. return Aug 31, 2026Partial shortageHydrochlorothiazide Losartan3 of 35 reported products affected · est. return Jul 7, 2026Partial shortageHydrochlorothiazide Valsartan5 of 27 reported products affected · est. return Jul 31, 2026Partial shortageOlmesartan Medoxomil Hydrochlorothiazide6 of 24 reported products affectedPartial shortageTelmisartan Hydrochlorothiazide3 of 23 reported products affected

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.